Filing Flows › OmniAb (OABI) › Guidance & outlook
OmniAb (OABI) guidance and outlook
OmniAb (OABI) raised some and lowered other parts of its guidance on Oct 30, 2026: Revenue $35.0M–$39.0M for FY2026; Operating expenses $83.0M–$87.0M for FY2026; Tax rate 0% for FY2026. OmniAb's 10-Q filed Oct 30, 2026 makes 8 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $35.0M–$39.0M | raised |
| Operating expenses | FY2026 | $83.0M–$87.0M | lowered |
| Tax rate | FY2026 | 0% | reaffirmed |
From the earnings release filed Oct 30, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts.
- Our partners can select a biological target to treat a disease and define the properties needed for therapeutic development or use certain of our technologies directly in their own laboratories.
- We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments.
- We believe our revenue will be materially driven by milestone and service revenue from our partnered programs, as well as xPloration platform sales, in the shorter term, and by royalty revenue from our partnered programs in the longer term.
- However, there is significant uncertainty in timing and likelihood of reaching marketing authorization in drug discovery and development, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue.
- For so long as the warrants remain out of the money, we do not expect warrant holders to exercise their warrants.
- Therefore, any cash proceeds that we may receive in relation to the exercise of such securities will be dependent on the trading price of our common stock.
- We anticipate that our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes.
OmniAb's latest quarter
OmniAb, Q3 2026: revenue $4.0M (+78% year over year), operating margin -409.9%, net loss $15.7M, operating cash flow $10.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did OmniAb raise or lower its guidance?
OmniAb (OABI) raised some and lowered other parts of its guidance on Oct 30, 2026: Revenue $35.0M–$39.0M for FY2026; Operating expenses $83.0M–$87.0M for FY2026; Tax rate 0% for FY2026.
What does OmniAb expect?
Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. Our partners can select a biological target to treat a disease and define the properties needed for therapeutic development or use certain of our technologies directly in their own laboratories. We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.